1. Emma Back MeTA Consultant MeTA country guidance note Movingtowards medicines data transparency, joint analysis and evidence-based policies to improve access to medicines 8 December 2009

2. Purpose of the guidance note

Toprovideadviceandguidanceto MeTA pilot countries specifically national Secretariats and multi-stakeholder groups as they take steps towards establishing a process of routine disclosure of key medicines data.

To provide sometoolsandexamplesto aid this process, sharecase studiesandlessonsfrom different countries, and identify potential sources of TA.

Broader purpose:

The note will help to ensurestandardization of reportingacross MeTA countries, which will in turn aidcomparison, monitoring and evaluation .

3. Proposed content

Recap of MeTA pilot phase goals and principles

Purpose of guidance note in this context

Phased approach towards increasing transparency, [accountability,] and evidence-based policy and practice; an ongoing cycle:

Diagnosis

Setting parameters; agreeing reporting format; agreeing process

Data collection / submission; data assessment

Multi-stakeholder discussion of the data

Data use - including for comms, advocacy and policy development

Reporting and monitoring

Using the phased approach in practice

Securing additional support

4. Questions for you

Does the step-wise approach make sense?

Will the proposed format of the guidance note give you what you need?

What else would you like to see in the note? What do you need most guidance on? TA priorities?

Do you have any case studies or lessons you would like to share through the guidance note?

Any data collection / disclosure / reporting formats?